HUYA enters strategic partnership with King's Lab

Aug 8 2011

HUYA Bioscience International, a leader in globalizing China's biopharmaceutical innovations, today announced a strategic partnership with the Shanghai Jiao Tong University School of Pharmacy King's Lab. The alliance with HUYA will assist King's Lab in accelerating the development of their novel drugs to international standards.

The agreement provides HUYA with access to and first review of certain novel therapeutic candidates owned or controlled by King's Lab. Correspondingly, King's Lab gains access to HUYA's expertise in drug development as well as its global network of pharmaceutical partners.

HUYA is one of the first companies to have recognized China's potential to help meet the global need for new preclinical and clinical stage compounds. The company is committed to facilitating and promoting the global development and commercialization of novel pharmaceutical products originating in China. HUYA has established a series of collaborations with leading universities and research institutions throughout China and has pioneered in-licensing innovative compounds from the country, utilizing its expertise to advance these compounds for global markets.

Shanghai Jiao Tong University School of Pharmacy King's Lab is a research laboratory situated at Shanghai Jiao Tong University's Minhang campus. The university boasts a large number of renowned professors and scientists. The School of Pharmacy is one of the youngest but fastest growing pharmacy schools in China. The King's Lab has been built for discovery and preclinical development of novel medicines for unmet medical needs. It is in collaboration with many leading domestic and international bio-pharmaceutical companies.

"Shanghai Jiao Tong University School of Pharmacy differs from many traditional pharmacy schools in China by having systematic research and educational programs to investigate emerging therapeutic areas," said Clement Gingras, HUYA's CTO and COO, China. "HUYA and Shanghai Jiao Tong University School of Pharmacy King's Lab mutually aspire to become the forefront of China's push for creating a competitive bioscience industry with pharmaceutical innovations."

Dr Yong X. Wang, Head of Shanghai Jiao Tong University School of Pharmacy King's Lab, commented, "Our goal is to become a leading center for pharmaceutical innovation, with HUYA's knowledge in developing China's innovative drug candidates. We have recently discovered several new target molecules and novel leads for chronic pain."